

Info Sheet for Technical description

No.0011

Organization

* Mandatory fields

Name of Organization*	REPROCELL Inc.	
Address, City, States, Zip, Country*	MetLife Shin-yokohama Bldg. 9F, 3-8-11 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa 222-0033	
URL	https://www.reprocell.com	
Brief Descriptions of Organization* (Approx. 100 words)	REPROCELL is dedicated to advancing human health through innovative products, services, and partnerships in regenerative medicine. We specialize in GMP-compliant manufacturing of custom iPSC and MSC Master Cell Banks using our proprietary StemRNA™ 5.0 technology. For drug discovery, our preclinical CRO offers custom assay services using live human tissues and 3D models. Our Central Laboratory Services support global clinical trials with high-quality genomic, proteomic, and cellular analyses. Through strategic acquisitions—BioServe®, Stemgent®, Alvetex®, and Bioptra®—REPROCELL offers a seamless workflow from tissue acquisition to clinical-grade stem cell development, enabling comprehensive support for regenerative medicine and drug development programs.	
Contact address	Name*	Daisuke Usui
	Department* / Position	COO, REPROCELL Inc.
	E-mail* / TEL	daisuke.usui@reprocell.jp

What kind of technology do you want to offer? *

- ☐ **A.** Clinical Development Pipelines
- ☒ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B)
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

→ Please see **Sheet [A]**→ Please see **Sheet [B]**→ Please see **Sheet [C]**

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☒ Yes
- ☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☐ Series C
- ☒ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	We can supply a non-confidential slide deck
☐ No	

Filled in by*

Date*

Sarah Emrini-Meissner, Head of Business -Stem Cells

August 8th, 2025

Sheet [B] Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.**Info Sheet for Technical overview**

No. B-0011

* Mandatoty fields

Title***REPROCELL StemRNA Clinical iPSCs and iMSCs and GMP Banks****Category***

- | | | |
|---|--|---|
| ☐ Facilities | ☐ Manufacturing equipment | ☐ Inspection equipment |
| ☒ Cells | ☐ Culture medium | ☐ Reagents |
| ☒ Cell banking | ☐ Storage / Container | ☐ Logistics |
| ☐ Cell / Viral vector manufacturing technology | | |

Description*

REPROCELL's StemRNA™ Clinical Seed iPSCs serve as a reliable foundation for various cell therapy programs by ensuring safety, consistency, and regulatory compliance. These iPSC Seed Clones can be expanded in a GMP environment to manufacture Master Cell Banks (MCB), which can be further downstream processed to generate a final drug product. The Seed Clones can also be used directly for StemEdit clinical gene editing before expansion to the MCB. REPROCELL offers GMP MCBs of iPSC, iMSC, and MSC manufactured by our stem cell experts in compliance with the regulatory standards and guidelines of the US FDA, European EMA, and Japanese PMDA.

Filled in by*

Sarah Emini-Meissner, Head of Business -Stem Cells

Date*

August 8th, 2025